These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 30695288

  • 1. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D, Tessier A, Daubigney A, Meissner WG, Schurhoff F, Boyer L, Godin O, Bulzacka E, Aouizerate B, Andrianarisoa M, Berna F, Capdevielle D, Chereau-Boudet I, D'Amato T, Dubertret C, Dubreucq J, Faget-Agius C, Lançon C, Mallet J, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Fond G, FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group.
    J Clin Psychiatry; 2019 Jan 08; 80(1):. PubMed ID: 30695288
    [Abstract] [Full Text] [Related]

  • 2. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
    Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, Kane JM, Saito E, Correll CU.
    J Am Acad Child Adolesc Psychiatry; 2015 Sep 08; 54(9):718-727.e3. PubMed ID: 26299293
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I.
    van Harten PN, Matroos GE, Hoek HW, Kahn RS.
    Schizophr Res; 1996 May 08; 19(2-3):195-203. PubMed ID: 8789918
    [Abstract] [Full Text] [Related]

  • 5. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A.
    J Clin Psychiatry; 1997 Jul 08; 58(7):318-22. PubMed ID: 9269253
    [Abstract] [Full Text] [Related]

  • 6. Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia.
    Rekhi G, Tay J, Lee J.
    J Psychopharmacol; 2022 Feb 08; 36(2):183-190. PubMed ID: 34979813
    [Abstract] [Full Text] [Related]

  • 7. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK, Zalar B, Breskvar K, Dolzan V.
    J Psychopharmacol; 2006 Nov 08; 20(6):829-33. PubMed ID: 16478753
    [Abstract] [Full Text] [Related]

  • 8. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
    Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM.
    J Clin Psychiatry; 2010 Apr 08; 71(4):463-74. PubMed ID: 20156410
    [Abstract] [Full Text] [Related]

  • 9. Tardive dyskinesia in Chinese patients with schizophrenia: Prevalence, clinical correlates and relationship with cognitive impairment.
    Liang Q, Wang D, Zhou H, Chen D, Xiu M, Cui L, Zhang X.
    J Psychiatr Res; 2022 Jul 08; 151():181-187. PubMed ID: 35489178
    [Abstract] [Full Text] [Related]

  • 10. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA.
    Schizophr Res; 2005 Sep 15; 77(2-3):129-39. PubMed ID: 15913962
    [Abstract] [Full Text] [Related]

  • 11. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset.
    Berna F, Misdrahi D, Boyer L, Aouizerate B, Brunel L, Capdevielle D, Chereau I, Danion JM, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Lancon C, Mallet J, Rey R, Passerieux C, Schandrin A, Schurhoff F, Tronche AM, Urbach M, Vidailhet P, Llorca PM, Fond G, FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group.
    Schizophr Res; 2015 Dec 15; 169(1-3):255-261. PubMed ID: 26589388
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):61-68. PubMed ID: 28839341
    [Abstract] [Full Text] [Related]

  • 13. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia.
    Uludag K, Wang DM, Goodman C, Chen DC, Wang L, Zhang X.
    Asian J Psychiatr; 2021 Dec 01; 66():102877. PubMed ID: 34638091
    [Abstract] [Full Text] [Related]

  • 14. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.
    Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, SOHO Study Group.
    J Clin Psychiatry; 2005 Sep 01; 66(9):1130-3. PubMed ID: 16187770
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH, Byun HJ.
    Clin Neuropharmacol; 2003 Sep 01; 26(6):312-6. PubMed ID: 14646611
    [Abstract] [Full Text] [Related]

  • 16. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H, Geraisy N, Schwartz M.
    J Clin Psychiatry; 1995 Apr 01; 56(4):167-70. PubMed ID: 7713856
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM, Chaturvedi SK, Desai G, Rao GN, Prakash O.
    Asian J Psychiatr; 2014 Jun 01; 9():31-5. PubMed ID: 24813033
    [Abstract] [Full Text] [Related]

  • 18. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review.
    Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R.
    Br J Psychiatry; 2002 Nov 01; 181():422-7. PubMed ID: 12411269
    [Abstract] [Full Text] [Related]

  • 19. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, Harricharan R.
    J Clin Psychopharmacol; 2008 Feb 01; 28(1):69-73. PubMed ID: 18204344
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.